Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25010652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Hironori Arai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 260 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Research and Development expenses.
Abstract (Originalsprache)
Due to the proliferation of genetic testing, pathogenic germline variants predisposing to hereditary hematological malignancy syndrome (HHMS) have been identified in an increasing number of genes. Consequently, the field of HHMS is gaining recognition among clinicians and scientists worldwide. Patients with germline genetic abnormalities often have poor outcomes and are candidates for allogeneic hematopoietic stem cell transplantation (HSCT). However, HSCT using blood from a related donor should be carefully considered because of the risk that the patient may inherit a pathogenic variant. At present, we now face the challenge of incorporating these advances into clinical practice for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and optimizing the management and surveillance of patients and asymptomatic carriers, with the limitation that evidence-based guidelines are often inadequate. The 2016 revision of the WHO classification added a new section on myeloid malignant neoplasms, including MDS and AML with germline predisposition. The main syndromes can be classified into three groups. Those without pre-existing disease or organ dysfunction; DDX41, TP53, CEBPA, those with pre-existing platelet disorders; ANKRD26, ETV6, RUNX1, and those with other organ dysfunctions; SAMD9/SAMD9L, GATA2, and inherited bone marrow failure syndromes. In this review, we will outline the role of the genes involved in HHMS in order to clarify our understanding of HHMS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
- Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Iidacho, Narita 286-0041, Japan.
- Department of Laboratory Medicine, National Cancer Center Hospital, Tsukiji, Chuoku 104-0045, Japan.
- Department of Medical Oncology and Translational Research, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8665, Japan.
ORCID-Profile: Hirotaka Matsui, SungGi Chi, Yosuke Minami
Förderung
- National Cancer Research and Development expenses
Zitieren
APA
Arai, H., Matsui, H., Chi, S., Utsu, Y., Masuda, S., Aotsuka, N., & Minami, Y. (2024). Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25010652
Vancouver
Arai H, Matsui H, Chi S, Utsu Y, Masuda S, Aotsuka N, et al. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25010652
BibTeX
@article{Arai2024,
author = {Arai, Hironori and Matsui, Hirotaka and Chi, SungGi and Utsu, Yoshikazu and Masuda, Shinichi and Aotsuka, Nobuyuki and Minami, Yosuke},
title = {Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25010652}
}
EUVIMED